BioSpace News Archive

ZAP Surgical Systems, Inc., developer and manufacturer of the ZAP-X® surgical robot for non-invasive ablation of brain tumors, announced that the Chairman of Foxconn Technology Co Ltd, Lu Jun-Fu, has joined the ZAP Surgical Board of Directors.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations.

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2022 second quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, July 26, 2022, and will host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

Emerson announced it has acquired Fluxa, a leader in the life sciences industry that uses software and modern technology architectures to accelerate the speed to market for new therapies, drugs and vaccines.

Aimmune Therapeutics, Inc., will present new data on PALFORZIA® [Peanut Allergen (Arachis hypogaea) Power-dnfp] at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Prague, Czech Republic on July 1-3, 2022.

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.

Sarepta Therapeutics, Inc. granted equity awards on June 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in June 2022.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that, on June 30, 2022, it entered into an amendment to its senior secured term loan with SWK Funding LLC.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase an aggregate of 50,925,365 shares of common stock.

3M has entered into an agreement to sell its rights to the Neoplast™ and Neobun™ brands and related assets in Thailand and certain other Southeast Asia countries, including the manufacturing assets of its Ladlumkaew, Thailand, facility to Selic Corp Public Company Limited, a company focusing on bonding innovation serving various industries.